Multiple Sclerosis Therapeutics Market Analysis By Drug Class (Immunomodulators, Immunosuppressant, Copaxone, Avonex, Gilenya, Tysabri, Betaseron, Tecfidera, Rebif, Ampyra, Aubagio, Extavia, Plegridy, Alemtuzumab, Glatopa, Siponimod, Ocrelizumab, Laquinimod, Zinbryta), By Mode of Administration (Oral, Injectable, Intravenous) And Segment Forecasts To 2024
The global multiple sclerosis therapeutics market is expected to reach USD 24.8 billion by 2024 according to a new report by Grand View Research, Inc.
The presence of high unmet clinical needs in developing regions is one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in spreading awareness among people regarding progressive multiple sclerosis and the symptoms associated with it. Some notable examples include the National Multiple Sclerosis Society (NMSS) in the U.S., Multiple Sclerosis International Federation in Canada, European Multiple Sclerosis Platform (EMSP), and the Multiple Sclerosis Society (MSC).
Reimbursement programs are also anticipated to enhance the penetration of multiple sclerosis drugs. For instance, In June 2014, Biogen Idec Canada, announced that its TECFIDERA drug for the treatment of MS is available for reimbursement in British Colombia through B.C PharmaCare.
The introduction of novel therapeutics with minimal dosage requirement and cost-effectiveness is further expected to favor market growth. For, instance Lemtrada by Sanofi needs to be administered 3-5 times per year as compared to Copaxone, which requires daily administration.
Further key findings from the study suggest:
The dominant drug class segment in 2015 was immunomodulators. Avonex, Betaseron, Copaxone, and Rebif were the key drugs capturing over 75% of market share in 2015.The introduction of Tecifedra, an oral immunomodulatory drug in 2015 has been a major breakthrough in this segment.
The declining revenue of Copaxone, Gilenya, Avonex, and Tysabri is forecasted by considering the factors such as limited usage rates of these drugs owing to the availability of highly potent FDA-approved oral drugs, Aubigio and Tecfidera
Immunosuppressant,on the other hand, is expected to witness significant growth of over 18.0%. The presence of a strong drug pipeline and its expected commercialization in the coming six years are some factors expected to drive market growth
In 2015, the injectable drugs market held the largest share owing to high prescription rates & price
North America dominated the overall multiple sclerosis therapeutics market with revenue estimates at over 13.0 billion in 2015. The increasing prevalence of multiple sclerosis, the introduction of new drugs, and high prices of drugs, such as Tysabri and Aubagio in the U.S., are some factors responsible for its dominance.
Major companies operating in this market are Biogen Idec, Teva Pharmaceuticals, Bayer Healthcare, Pfizer, Sanofi Aventis, Merck, Novartis, and AbbVie. Market players are upgrading the product portfolio by launching generic versions to sustain its market position. For instance, in 2015, Novartis launched a generic version of Copaxone named Glatopa in the U.S.
The presence of high unmet clinical needs in developing regions is one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in spreading awareness among people regarding progressive multiple sclerosis and the symptoms associated with it. Some notable examples include the National Multiple Sclerosis Society (NMSS) in the U.S., Multiple Sclerosis International Federation in Canada, European Multiple Sclerosis Platform (EMSP), and the Multiple Sclerosis Society (MSC).
Reimbursement programs are also anticipated to enhance the penetration of multiple sclerosis drugs. For instance, In June 2014, Biogen Idec Canada, announced that its TECFIDERA drug for the treatment of MS is available for reimbursement in British Colombia through B.C PharmaCare.
The introduction of novel therapeutics with minimal dosage requirement and cost-effectiveness is further expected to favor market growth. For, instance Lemtrada by Sanofi needs to be administered 3-5 times per year as compared to Copaxone, which requires daily administration.
Further key findings from the study suggest:
The dominant drug class segment in 2015 was immunomodulators. Avonex, Betaseron, Copaxone, and Rebif were the key drugs capturing over 75% of market share in 2015.The introduction of Tecifedra, an oral immunomodulatory drug in 2015 has been a major breakthrough in this segment.
The declining revenue of Copaxone, Gilenya, Avonex, and Tysabri is forecasted by considering the factors such as limited usage rates of these drugs owing to the availability of highly potent FDA-approved oral drugs, Aubigio and Tecfidera
Immunosuppressant,on the other hand, is expected to witness significant growth of over 18.0%. The presence of a strong drug pipeline and its expected commercialization in the coming six years are some factors expected to drive market growth
In 2015, the injectable drugs market held the largest share owing to high prescription rates & price
North America dominated the overall multiple sclerosis therapeutics market with revenue estimates at over 13.0 billion in 2015. The increasing prevalence of multiple sclerosis, the introduction of new drugs, and high prices of drugs, such as Tysabri and Aubagio in the U.S., are some factors responsible for its dominance.
Major companies operating in this market are Biogen Idec, Teva Pharmaceuticals, Bayer Healthcare, Pfizer, Sanofi Aventis, Merck, Novartis, and AbbVie. Market players are upgrading the product portfolio by launching generic versions to sustain its market position. For instance, in 2015, Novartis launched a generic version of Copaxone named Glatopa in the U.S.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MULTIPLE SCLEROSIS THERAPEUTICS INDUSTRY OUTLOOK
3.1 Market Segmentation
3.2 Market Size and Growth Prospects
3.2.1 Market driver analysis
3.2.1.1 Increasing global prevalence of target disease
3.2.1.2 Awareness programs
3.2.1.3 Presence of reimbursement policies.
3.2.1.4 Strong product pipeline.
3.2.2 Market restraint analysis
3.2.3 Multiple sclerosis therapeutics market - Key market restraint analysis
3.2.3.1 Side-effects and risks
3.2.3.2 High price
3.3 Key Opportunities Prioritized
3.4 Multiple sclerosis therapeutics - PESTEL Analysis
CHAPTER 4 MULTIPLE SCLEROSIS THERAPEUTICS DRUG CLASS OUTLOOK
4.1 Multiple sclerosis therapeutics Market Share by Drug Class, 2015 & 2024
4.2 Immunomodulators
4.2.1 Immunomodulators market, 2012 - 2024 (USD Million)
4.3 Immunosuppressant
4.3.1 Immunosuppressantmarket, 2012 - 2024 (USD Million)
CHAPTER 5 MULTIPLE SCLEROSIS THERAPEUTICS MODE OF ADMINISTRATION OUTLOOK
5.1 Multiple sclerosis therapeutics Market Share by Mode of Administration, 2015 & 2024
5.2 Oral
5.2.1 Oral market, 2012 - 2024 (USD Million)
5.3 Injectable
5.3.1 Injectablemarket, 2012 - 2024 (USD Million)
5.4 Intravenous
5.4.1 Intravenousmarket, 2012 - 2024 (USD Million)
CHAPTER 6 MULTIPLE SCLEROSIS THERAPEUTICS REGIONAL OUTLOOK
6.1 Multiple sclerosis therapeutics Market Share by Region, 2015 & 2024
6.2 North America
6.2.1 North America Multiple sclerosis therapeutics Market, 2012-2024 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.2.3 Canada
6.2.3.1 Canada multiple sclerosis therapeutics market, 2012 - 2024 (USD Million)
6.3 Europe
6.3.1 Europe Multiple sclerosis therapeutics Market, 2012-2024 (USD Million)
6.3.2 UK
6.3.2.1 UK Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.4 Asia Pacific Multiple sclerosis therapeutics Market
6.4.1 Asia Pacific Multiple sclerosis therapeutics Market, 2012-2020 (USD Million)
6.4.2 China
6.4.2.1 China Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.4.3 India
6.4.3.1 India Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.5 Latin America
6.5.1 Latin America Multiple sclerosis therapeutics Market, 2012 - 2022 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.6 MEA
6.6.1 MEA Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Teva
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Pfizer
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Biogen Idec
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Bayer Healthcare
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 Genzyme (SANOFI)
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MULTIPLE SCLEROSIS THERAPEUTICS INDUSTRY OUTLOOK
3.1 Market Segmentation
3.2 Market Size and Growth Prospects
3.2.1 Market driver analysis
3.2.1.1 Increasing global prevalence of target disease
3.2.1.2 Awareness programs
3.2.1.3 Presence of reimbursement policies.
3.2.1.4 Strong product pipeline.
3.2.2 Market restraint analysis
3.2.3 Multiple sclerosis therapeutics market - Key market restraint analysis
3.2.3.1 Side-effects and risks
3.2.3.2 High price
3.3 Key Opportunities Prioritized
3.4 Multiple sclerosis therapeutics - PESTEL Analysis
CHAPTER 4 MULTIPLE SCLEROSIS THERAPEUTICS DRUG CLASS OUTLOOK
4.1 Multiple sclerosis therapeutics Market Share by Drug Class, 2015 & 2024
4.2 Immunomodulators
4.2.1 Immunomodulators market, 2012 - 2024 (USD Million)
4.3 Immunosuppressant
4.3.1 Immunosuppressantmarket, 2012 - 2024 (USD Million)
CHAPTER 5 MULTIPLE SCLEROSIS THERAPEUTICS MODE OF ADMINISTRATION OUTLOOK
5.1 Multiple sclerosis therapeutics Market Share by Mode of Administration, 2015 & 2024
5.2 Oral
5.2.1 Oral market, 2012 - 2024 (USD Million)
5.3 Injectable
5.3.1 Injectablemarket, 2012 - 2024 (USD Million)
5.4 Intravenous
5.4.1 Intravenousmarket, 2012 - 2024 (USD Million)
CHAPTER 6 MULTIPLE SCLEROSIS THERAPEUTICS REGIONAL OUTLOOK
6.1 Multiple sclerosis therapeutics Market Share by Region, 2015 & 2024
6.2 North America
6.2.1 North America Multiple sclerosis therapeutics Market, 2012-2024 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.2.3 Canada
6.2.3.1 Canada multiple sclerosis therapeutics market, 2012 - 2024 (USD Million)
6.3 Europe
6.3.1 Europe Multiple sclerosis therapeutics Market, 2012-2024 (USD Million)
6.3.2 UK
6.3.2.1 UK Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.4 Asia Pacific Multiple sclerosis therapeutics Market
6.4.1 Asia Pacific Multiple sclerosis therapeutics Market, 2012-2020 (USD Million)
6.4.2 China
6.4.2.1 China Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.4.3 India
6.4.3.1 India Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.5 Latin America
6.5.1 Latin America Multiple sclerosis therapeutics Market, 2012 - 2022 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.6 MEA
6.6.1 MEA Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Teva
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Pfizer
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Biogen Idec
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Bayer Healthcare
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 Genzyme (SANOFI)
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
